A multicentre comparison of quantitative 90Y PET/CT for dosimetric purposes after radioembolization with resin microspheres

published_or_final_versio

Abdo-Man: a 3D-printed anthropomorphic phantom for validating quantitative SIRT.

Background The use of selective internal radiation therapy (SIRT) is rapidly increasing, and the need for quantification and dosimetry is becoming more widespread to facilitate treatment planning and verification. The aim of this project was to develop an anthropomorphic phantom that can be used as a validation tool for post-SIRT imaging and its application to dosimetry.Method The phantom design was based on anatomical data obtained from a T1-weighted volume-interpolated breath-hold examination (VIBE) on a Siemens Aera 1.5 T MRI scanner. The liver, lungs and abdominal trunk were segmented using the Hermes image processing workstation. Organ volumes were then uploaded to the Delft Visualization and Image processing Development Environment for smoothing and surface rendering. Triangular meshes defining the iso-surfaces were saved as stereo lithography (STL) files and imported into the Autodesk® Meshmixer software. Organ volumes were subtracted from the abdomen and a removable base designed to allow access to the liver cavity. Connection points for placing lesion inserts and filling holes were also included. The phantom was manufactured using a Stratasys Connex3 PolyJet 3D printer. The printer uses stereolithography technology combined with ink jet printing. Print material is a solid acrylic plastic, with similar properties to polymethylmethacrylate (PMMA).Results Measured Hounsfield units and calculated attenuation coefficients of the material were shown to also be similar to PMMA. Total print time for the phantom was approximately 5 days. Initial scans of the phantom have been performed with Y-90 bremsstrahlung SPECT/CT, Y-90 PET/CT and Tc-99m SPECT/CT. The CT component of these images compared well with the original anatomical reference, and measurements of volume agreed to within 9 %. Quantitative analysis of the phantom was performed using all three imaging techniques. Lesion and normal liver absorbed doses were calculated from the quantitative images in three dimensions using the local deposition method.Conclusions 3D printing is a flexible and cost-efficient technology for manufacture of anthropomorphic phantom. Application of such phantoms will enable quantitative imaging and dosimetry methodologies to be evaluated, which with optimisation could help improve outcome for patients

The uptake of soluble and nanoparticulate imaging isotope in model liver tumours after intra-venous and intra-arterial administration

Delivery of chemotherapeutic drugs to tumours by reformulation as nanoparticles has often been proposed as a means of facilitating increased selective uptake, exploiting the increased permeability of the tumour vasculature. However realisation of this improvement in drug delivery in cancer patients has met with limited success. We have compared tumour uptake of soluble Tc99m-pertechnetate and a colloid of nanoparticles with a Tc99m core, using both intra-venous and intra-arterial routes of administration in a rabbit liver VX2 tumour model. The radiolabelled nanoparticles were tested both in untreated and cationised form. The results from this tumour model in an internal organ show a marked advantage in intra-arterial administration over the intra-venous route, even for the soluble isotope. Tumour accumulation of nanoparticles from arterial administration was augmented by cationisation of the nanoparticle surface with histone proteins, which consistently facilitated selective accumulation within microvessels at the periphery of tumours.Sources of support for this research: Sirtex Medical Ltd, Sydney Australia

Primary standardization of SIR-Spheres based on the dissolution of the 90 Y-labeled resin microspheres

International audienceThe project "Metrology for molecular radiotherapy" is a collaborative European project initiated to bring together expertize in ionizing radiation metrology and nuclear medicine research. This project deals with the development of personalized dosimetry to individual patients who are undergoing molecular radiotherapy (also known as targeted radionuclide therapy). The general aim is to provide a metrological traceability to primary standards for individual dosimetry in the case of molecular radiotherapy. In particular, one objective is the standardization of Y-90-labeled resin microspheres SIR-Spheres (Sirtex, Sydney, Australia) used for the treatment of liver cancer by radioembolization. The present paper describes the primary measurements carried out using the Triple to Double Coincidence Ratio (TDCR) method applied after the complete dissolution of the SIR-Spheres in the Sirtex vial. A method for the dissolution was developed to optimize the homogeneity of the solution to enable the primary measurements based on Cherenkov and liquid scintillation counting. A comprehensive description of the protocol implemented for the microsphere dissolution is reported. First calibration factors obtained with the reference ionization chambers at LNE-LNHB are also given

Plasma hydroxy metronidazole/metronidazole ratio in anti-HCV carriers with and without apparent liver disease

Aims: To evaluate plasma hydroxy-metronidazole/metronidazole ratio as a dynamic liver function test in HCV-infected individuals with/without liver disease, in the absence of liver cirrhosis. Methods: Metronidazole was administered intravenously in healthy volunteers, asymptomatic anti-HCV-positive blood donors, and in chronic hepatitis C patients. Serology to HCV was determined by a second generation assay and confirmed by gelatin particle agglutination test using recombinant antigens C22-3 and C200. Plasma concentration of metronidazole and hydroxy-metronidazole was measured by high performance liquid chromatography in samples collected 5, 10, 20 and 30 min following the end of metronidazole infusion. Results: Chronic hepatitis C patients had abnormal liver enzymes, while healthy volunteers and anti-HCV-positive blood donors had normal liver biochemistry tests. Plasma metronidazole concentration was similar,in all groups studied. Plasma hydroxy-metronidazole/metronidazole ratio was significantly reduced in HCV-infected subjects, an effect observed 10 min after the end of drug infusion. Conclusions: Metronidazole clearance is impaired in anti-HCV-positive blood donors and chronic hepatitis C patients, indicating that HCV is capable of affecting liver function at early stages of the disease. The metronidazole clearance test can detect impaired liver function in HCV-infected individuals even in the absence of liver cirrhosis.462176180Kuo, G., Choo, Q.L., Alter, H.J., An assay for circulating antibodies to a major etiologic virus of human non-A, non-B hepatitis (1989) Science, 244, pp. 359-362Booth, J.C.L., Brown, J.L., Thomas, H.C., The management of chronic hepatitis C virus infection (1995) Gut, 37, pp. 449-454Dusheiko, G.M., Hepatitis C virus (1992) Recent Advances in Gastroenterology. 9th Ed., pp. 195-216. , ed Pounder RE, Edinburgh: Churchill LivingstoneAlter, M.J., Margolis, H.S., Krawczynsky, K., The natural history of community-acquired hepatitis C in the United States (1992) New Engl J Med, 327, pp. 1899-1905Alberti, A., Morsica, G., Chemello, L., Hepatitis C viraemia and liver disease in symptom-free individuals with anti HCV (1992) Lancet, 340, pp. 697-698Brillianti, S., Foli, M., Gaiani, S., Persistent hepatitis C viraemia without liver disease (1993) Lancet, 341, pp. 464-465Hartmann, A.I., Bircher, H., Creutzfeld, W., Superiority of the Child-Pugh Classification to quantitative liver function test for assessing prognosis of liver cirrhosis (1989) Scand J Gastroenterol, 24, pp. 269-276Wang, T., Kleber, G., Steelaard, F., Caffeine elimination: A test of liver function (1985) Klin Wochenschr, 63, pp. 1124-1128Shiffman, M.L., Fisher, R.A., Sanyal, A.J., Hepatic lidocaine metabolism and complications of cirrhosis. Implications for assessing patient priority for hepatic transplantation (1992) Transplantation, 55, pp. 830-835Muscará, M.N., Pedrazzoli, J.J., Miranda, E.L., Plasma hydroxy metronidazole/metronidazole ratio in patients with liver disease and in healthy volunteers (1995) Br J Clin Pharmacol, 40, pp. 477-480Saeed, A., Al-Admawi, A., Al-Rasheed, A., Hepatitis C virus infection in Egyptian volunteer blood donors in Riyadh (1991) Lancet, 338, pp. 459-460Muscará, M.N., De Nucci, G., Bioavailability of four pharmaceutical formulations of metronidazole tested on normal healthy volunteers (1991) Braz J Med Biol Res, 24, pp. 1251-1260Shiffman, M.L., Luketic, V.A., Sanyal, A.J., Hepatic lidocaine metabolism and liver histology in patients with chronic hepatitis and cirrhosis (1994) Hepatology, 19, pp. 933-940Shindo, M., Arai, K., Sokawa, Y., The virological and histological states of anti-Hepatitis C Virus-positive subjects with normal liver biochemical values (1995) Hepatology, 2, pp. 418-425Alberti, A., Chemello, L., Cavalletto, D., Antibody to hepatitis C virus and liver disease in volunteer blood donors (1991) Ann Intern Med, 114, pp. 1010-1012Esteban, J.I., Lopez-Talavera, J.C., Genesca, J., High rate of infectivity and liver disease in blood donors with antibodies to hepatitis C virus (1991) Ann Intern Med, 115, pp. 443-449Dusheiko, G., Schmilovitz-Weiss, H., Brown, D., Hepatitis C virus genotypes: An investigation of type-specific differences in geographic origin and disease (1994) Hepatology, 19, pp. 13-18Prati, D., Capelli, C., Zanella, A., Influence of different hepatitis C virus genotypes on the course of asymptomatic hepatitis C virus infection (1996) Gastroenterology, 110, pp. 178-183Zeuzem, S., Franke, A., Lee, J.H., Phylogenetic analysis of hepatitis C virus isolates and their correlation to viraemia, liver function tests, and histology (1996) Hepatology, 24, pp. 1003-1009Loft, S., Otton, S.V., Lennard, M.S., Characterization of metronidazole metabolism by human liver microsomes (1991) Biochem Pharmacol, 41, pp. 1127-1134Haller, W., In vitro activity of the two principal oxidative metabolites of metronidazole against Bacteroides fragilis and related species (1982) Antimicrob Agents Chemother, 22, pp. 165-166Renton, K.W., Knickle, L.C., Regulation of hepatic cytochrome 450 during infectious disease (1990) Can J Physiol Pharmacol, 68, pp. 777-781Morgan, E.T., Norman, C.A., Pre-translational suppression of cytochrome P450 (IIC11) gene expression in rat liver after administration of interferon inducers (1990) Drug Metab Dispos, 18, pp. 649-653Thal, C., El Kahwaji, J., Loeper, J., Administration of high doses of human recombinant interleukin 2 decreases the expression of several cytochrome P450 in the rat (1993) J Pharmacol Exp Ther, 268, pp. 515-521Abdel-Razzak, Z., Loyer, P., Fautrel, A., Cytokines down-regulate expression of major cytochrome P450 enzymes in adult human hepatocytes in primary culture (1993) Mol Pharmacol, 44, pp. 707-715Tapner, M., Liddle, C., Goodwin, B., Interferon gamma down-regulates cytochrome P450 genes in primary cultures of well-differentiated rat hepatocytes (1996) Hepatology, 24, pp. 367-373Abdel-Razzak, Z., Loyer, P., Fautrel, A., Cytokines down-regulate expression of major cytochrome P450 enzymes in adult human hepatocytes in primary culture (1993) Mol Pharmacol, 44, pp. 707-715Cacciarelli, T.V., Martinez, O.M., Gish, R.G., Immunoregulatory cytokines in chronic hepatitis C virus infection: Pre- and posttreatment with interferon alpha (1996) Hepatohgy, 24, pp. 6-9Napoli, J., Bishop, C.A., McGuiness, P.H., Progressive liver injury in chronic hepatitis C infection correlates with increased intrahepatic expression of Th1-associated cytokines (1996) Hepatology, 24, pp. 759-765Cerny, A., Chisari, F.V., Immunological aspects of HCV infection (1994) Intervirology, 37, pp. 119-125Gonzalez-Peralta, R.P., Davis, G.L., Lau, J.Y., Pathogenetic mechanisms of hepatocellular damage in chronic hepatitis C (1994) J Hepatol, 21, pp. 255-259Battegay, M., Immunity of hepatitis C virus: A further piece of the puzzle (1996) Gastroenterology, 24, pp. 961-963Shakil, A.O., Conry-Cantilena, C., Alter, H.J., Volunteer blood donors with antibody to hepatitis C virus: Clinical, biochemical virological and histological features (1995) Ann Intern Med, 123, pp. 330-337Mosnier, J.F., Scoazec, J.Y., Marcelin, P., Expression of cytokine-dependent immune adhesion molecules by hepatocytes (1994) Gastroenterology, 107, pp. 1457-1468Lunel, F., Abuaf, N., Frangeul, L., Liver/kidney microsome antibody type 1 and hepatitis C virus infection (1992) Hepatology, 16, pp. 630-636Tran, A., Quaranta, J.-F., Benzaken, S., High prevalence of thyroid autoantibodies in a prospective series of patients with chronic hepatitis C before Interferon therapy (1993) Hepatalogy, 18, pp. 253-257Michel, G., Ritter, A., Gerken, G., Anti-GOR and hepatitis C virus in autoimmune liver diseases (1992) Lancet, 339, pp. 267-268Lenzi, M., Ballardini, G., Fusconi, M., Type 2 autoimmune hepatitis and hepatitis C virus infection (1990) Lancet, 335, pp. 258-259Durant, J.M., Lefevre, P., Harle, J.R., Cutaneous vasculitis and cryoglobulinaemia type II associated with hepatitis C virus infection (1991) Lancet, 337, pp. 499-500Loeper, J., Descatoire, V., Maurice, M., Cytochrome P450 in human hepatocyte plasma membrane: Recognition by several autoantibodies (1993) Gastroenterology, 104, pp. 203-216Lunel, F., Abuaf, N., Frangeul, L., Liver/kidney microsome antibody type 1 and hepatitis C virus infection (1992) Hepatology, 16, pp. 630-636Waxrnan, D.J., Lapenson, D.P., Krissnan, M., Antibodies to liver/kidney microsome in chronic active hepatitis recognize specific forms of hepatic cytochrome P450 (1988) Gastroenterology, 95, pp. 1326-1331Manns, M.P., Griffin, K.J., Sullivan, K.F., LKM-1 autoantibodies recognize a short linear sequence in P450IID6, a cytochrome P450 Monooxygenase (1991) J Clin Invest, 88, pp. 1370-137